Clinical Study for Cefepine in the Treatment of Moderate and Severe Bacterial Infections

李湘燕,赵彩芸,郝凤兰,肖永红,范敏华,张洁,唐子勇,谢倩,姚婉贞,沈宁,刘文虎,王刚,张杰,董淑文

DOI: https://doi.org/10.3321/j.issn:1003-3734.2005.06.031

2005-01-01

Abstract:Objective: To compare the efficacy and safety of cefepime manufactured in China versus imported in the treatment of moderate to severe bacterial infections. Methods: Of 278 patients with lower respiratory tract infection and urinary tract infection enrolled in a randomized, multi-center, single-blind, parallel-controlled clinical trial, 258 were randomized to administer either domestic (n=130) or imported (n=128) cefepime for 7～14 days. For urinary tract infection and respiratory tract infection, patients were intravenously infused with cefepime of 1 g and 2 g, respectively, twice daily. Results: The overall efficacy rate, bacterial eradication rate and incidence rate of adverse events had not shown significant differences for domestic and imported cefepime, i. e. , 94.62 % vs 89.06 %, 95.45 % vs 97.06 % and 6.52 % vs 5.71%, respectively. Conclusion: Domestic cefepime offers an alternative in the treatment of moderate and severe bacterial infections.